Use of Proteomic Methods to Identify Serum Biomarkers Associated with Rat Liver Toxicity or Hypertrophy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Our objectives were to identify serum marker proteins in rats that might serve as sensitive indicators of hepatomegaly, hepatocellular necrosis, or hepatobiliary injury and to use them to analyze data from a collaborative proteomics project. Methods: In each of 4 studies comprising the collaborative project, rats were given 1 of 4 compounds that target the liver through different mechanisms. Sera and liver samples were collected by terminal bleeds at 1 of 3 postdose time points. Sera were depleted of major secretory proteins and then separated into protein features by 2-dimensional gel electrophoresis (2DGE). Liver specimens were also processed and subjected to 2DGE. Protein spots that significantly increased or decreased in quantity after drug treatment were recovered, digested, analyzed by mass spectroscopy, and compared with available databases for identification. Criteria for further consideration were (a) temporal expression (i.e., increase or decrease at early, fulminant, or recovery periods), (b) known biological function, (c) probable hepatic origin, and (d) any previous association with toxicity in published studies. Markers that changed significantly at the early time point were important because of their potential sensitivity for signaling minimal damage. Results: Vitamin D–binding protein, paraoxonase, cellular retinol-binding protein, malate dehydrogenase, F-protein, and purine nucleoside phosphorylase were identified as empirically confirmed serum markers for hepatic effects in drug-treated rats. Conclusion: Proteomics can be applied for the identification and confirmation of peripheral biomarkers for altered liver function after toxicant exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hemopexin: structure, function, and regulation
Tolosano, E., & Altruda, F. (2002) · DNA and Cell Biology · doi:10.1089/104454902753759717 · Cited by 426
Cited by
The current state of serum biomarkers of hepatotoxicity
Ozer, J., Ratner, M., Shaw, M., Bailey, W., & Schomaker, S. (2008) · Toxicology · doi:10.1016/j.tox.2007.11.021 · Cited by 1,269
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
“Many studies have been conducted to identify more reliable and sensitive early blood markers for liver injury by using various high throughput technologies such as protein mass spectrometry and gene expression arrays (3, 4).”
BackgroundPlasma MicroRNA-122 as a Biomarker for Viral-, Alcohol-, and Chemical-Related Hepatic Diseases
Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., Fei, M., & Sun, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147850 · Cited by 415
Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry
Luque-Garcia, J. L., & Neubert, T. A. (2007) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.11.054 · Cited by 212
Models of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
Metadata
- Authors
- Amacher, D. E., Adler, R., Herath, A., & Townsend, R. R.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-01
- Volume
- 51
- Issue
- 10
- Pages
- 1796-1803
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2130595300
- Cited by
- 92
- References
- 1
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.